DSS (DSS) Q2 2025 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2025 increased 27% year-over-year, driven by growth in Printed Products and Securities segments, while Commercial Lending revenue declined due to loans on non-accrual status.

• Net loss for the six months ended June 30, 2025 was $7.9 million, a 21% improvement compared to the $10.1 million net loss in the prior year period.

• The company operates five main business lines: Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing.

Financial highlights

• Total revenue for the six months ended June 30, 2025 was $10.2 million, up from $8.1 million year-over-year.

• Operating loss for the six months ended June 30, 2025 was $7.2 million, compared to $9.6 million in the prior year period.

• Net loss attributable to common stockholders for the six months ended June 30, 2025 was $6.9 million, or $(0.78) per share, versus $8.8 million, or $(1.24) per share, in the prior year.

• Cash and cash equivalents as of June 30, 2025 were $9.4 million.

• Gain on investments of $1.6 million and a loss on sale of real estate of $0.7 million were recorded in the first half of 2025.

Outlook and guidance

• Management believes it has sufficient cash and access to capital to meet requirements for at least the next 12 months.

• The company is taking steps to reduce expenses and cash burn across all business lines.

• Substantial doubt remains about the company's ability to continue as a going concern due to ongoing operating losses and negative cash flows.